Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.
Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.
Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
SBRT Emerges as Viable Treatment for Localized Prostate Cancer
Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.
The Evolving Landscape of Prostate Cancer Management
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.